Atlas Trials

Glaucoma, Neovascular

12 clinical trials · Condition

Sort:Newest firstOldest first

◉ Watch Glaucoma, Neovascular

RecordFirmDate
INTEGRAL Study: A Longitudinal Study of Surgeries and Lasers in Glaucoma: Long-term Results and Success Predictors Analysed From a Large-scale Retrospective and Prospective Glaucoma Register (NCT04381611)Dr. Kaweh Mansouri2019-01-15
Study to Learn How the Drug Aflibercept Works in in Japanese Patients With Increased Eye Pressure That is Caused by New Blood Vessels Growing in the Eye (Neovascular Glaucoma or NVG). Safety of the Drug and Patients' Tolerability of the Drug Injection is Also Studied (NCT03639675)Bayer2018-10-03
Intracameral Versus Intravitreal Bevacizumab Injection in NVG: RCT (NCT03648814)Prince of Songkla University2018-08-01
Treatment Outcomes of MicroPulse Trans-scleral Cyclophotocoagulation in Uncontrolled Glaucoma (NCT03187418)Centre hospitalier de l'Université de Montréal (CHUM)2017-06-19
Intravitreal Ranibizumab (Lucentis®) for Neovascular Glaucoma- a Randomized Controlled Study (NCT02914626)LEANDRO CABRAL ZACHARIAS2016-10-01
Japanese Phase 3 Study of Aflibercept in Neovascular Glaucoma Patients (NCT02396316)Bayer2015-04-02
Baerveldt (BGI) Valve Versus Ahmed(AGV) Valve in Management of Difficult Glaucoma Cases (NCT04215575)Ain Shams University2014-01-01
An Open-label Extended Clinical Protocol of Ranibizumab to Evaluate Safety and Efficacy in Rare VEGF Driven Ocular Diseases. (NCT01908816)Novartis Pharmaceuticals2013-09-26
Intravitreal Ranibizumab Injection as Adjuvant in the Treatment of Postvitrectomy Diabetic Vitreous Hemorrhage Accompanied by Neovascular Glaucoma (NCT02647515)Ruijin Hospital2013-01-01
The Outcome of Ahmed Glaucoma Valve in Difficult Glaucoma Cases (NCT04214847)Ain Shams University2012-02-01
Intravitreous Ranibizumab as Adjunctive Treatment for Trabeculectomy in Neovascular Glaucoma (NCT01922154)Siriraj Hospital2009-02-01

Track Glaucoma, Neovascular automatically

Every clearance here is in the API, with alerts when new ones post.